DeutschNewstral
Article
jdsupra.com on 2019-11-06 18:27
FDA Approves Sandoz’s Biosimilar Pegfilgrastim
Related news
- FDA Approves Second Pegfilgrastim Biosimilar, a First for Coherusjdsupra.com
- FDA Approves Celltrion’s Trastuzumab Biosimilarjdsupra.com
- U.S. Biosimilar Launches: Mylan/Biocon’s Trastuzumab, Sandoz’s Pegfilgrastimjdsupra.com
- FDA Approves Pfizer’s Adalimumab Biosimilar ABRILADAjdsupra.com
- FDA Approves Sandoz’s Biosimilar of Enbrel®jdsupra.com
- FDA Approves 25th Biosimilarjdsupra.com
- FDA Approves First Biosimilar: Sandoz’s Zarxio®jdsupra.com
- FDA accepts Coherus’s resubmitted pegfilgrastim biosimilar applicationjdsupra.com
- European Biosimilar Approval Updates: Adalimumab, Pegfilgrastimjdsupra.com
- FDA Approves First Rituximab Biosimilarjdsupra.com
- Mundipharma Launches Pegfilgrastim Biosimilar in Europejdsupra.com
- BREAKING NEWS: FDA Approves Sandoz’s Erelzi, biosimilar to Enbrel (etanercept)jdsupra.com
- European Commission Approves Pegfilgrastim Biosimilarsjdsupra.com
- US FDA Issues CRL For Biocon and Mylan’s Pegfilgrastim Biosimilarjdsupra.com
- FDA Accepts Fresenius Kabi Pegfilgrastim Biosimilar Candidate for Reviewjdsupra.com
- Lupin Announces FDA Acceptance of aBLA for Pegfilgrastim Biosimilarjdsupra.com
- Biosimilar Pipeline Developments: Rituximab, Adalimumab, Eculizumab, Infliximab, Pegfilgrastimjdsupra.com
- Amgen and Accord End Filgrastim, Pegfilgrastim Biosimilar Litigationjdsupra.com
- FDA Approves Samsung Bioepis’s Trastuzamab Biosimilarjdsupra.com
- FDA Approves Sandoz Filgrastim Biosimilarjdsupra.com